149 related articles for article (PubMed ID: 36379923)
1. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).
Brunner AM; Gavralidis A; Ali NA; Hunter A; Komrokji R; Zeidan A; Sallman DA
Blood Cancer J; 2022 Nov; 12(11):153. PubMed ID: 36379923
[TBL] [Abstract][Full Text] [Related]
2. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
Komrokji RS; Al Ali NH; Sallman D; Padron E; DeZern AE; Barnard J; Roboz GJ; Garcia-Manero G; List A; Steensma DP; Sekeres MA
Cancer Med; 2021 Jan; 10(2):447-453. PubMed ID: 33350168
[TBL] [Abstract][Full Text] [Related]
3. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Rajakumaraswamy N; Gandhi M; Wei AH; Sallman DA; Daver NG; Mo S; Iqbal S; Karalliyadda R; Chen M; Wang Y; Vyas P
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):260-268.e2. PubMed ID: 38216397
[TBL] [Abstract][Full Text] [Related]
4. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
Jabbour E; Strati P; Cabrero M; O'Brien S; Ravandi F; Bueso-Ramos C; Wei Q; Hu J; Abi Aad S; Short NJ; Dinardo C; Daver N; Kadia T; Wierda W; Wei Y; Colla S; Borthakur G; Cortes J; Estrov Z; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Apr; 92(4):351-358. PubMed ID: 28076892
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Nazha A; Sekeres MA; Garcia-Manero G; Barnard J; Al Ali NH; Roboz GJ; Steensma DP; DeZern AE; Zimmerman C; Jabbour EJ; Zell K; List AF; Kantarjian HM; Maciejewski JP; Komrokji RS;
Leuk Res; 2016 Feb; 41():43-7. PubMed ID: 26777537
[TBL] [Abstract][Full Text] [Related]
8. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
12. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
[TBL] [Abstract][Full Text] [Related]
15. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
[TBL] [Abstract][Full Text] [Related]
16. The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes.
Hirst WJ; Mufti GJ
Leuk Res; 1994 Nov; 18(11):797-804. PubMed ID: 7967705
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
18. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
GenoMed4All consortium
Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
